Enoxaparin Sodium Injection, USP, 30 mg/0.3 mL, packaged in 0.3 mL prefilled syringes further pac...
FDA Drug Recall #D-0597-2025 — Class II — August 5, 2025
Recall Summary
| Recall Number | D-0597-2025 |
| Classification | Class II — Moderate risk |
| Date Initiated | August 5, 2025 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Cardinal Health Inc. |
| Location | Dublin, OH |
| Product Type | Drugs |
| Quantity | 10 bags |
Product Description
Enoxaparin Sodium Injection, USP, 30 mg/0.3 mL, packaged in 0.3 mL prefilled syringes further packaged in bags of 5 prefilled syringes, Rx Only, Dist. by: Sandoz Inc., Princeton, NJ 08540, Outer package - NDC 55154-3543-5, Inner label - NDC 0781-3238-01
Reason for Recall
Correct Labeled Product Mispack: Bags labeled for Enoxaparin Sodium Injection, 80 mg/0.8 mL, contained Enoxaparin Sodium Injection, 30 mg/0.3 mL
Distribution Pattern
KS
Lot / Code Information
Outer package - NDC 55154-3543-5, Lot SAD08033AA Inner label - NDC 0781-3238-01, Lot SAF13211A
Other Recalls from Cardinal Health Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0573-2025 | Class II | RECOMBINATE, [Antihemophilic Factor (Recombinan... | Jul 30, 2025 |
| D-0571-2025 | Class II | Xolair (omalizumab injection), 150 mg/ml, 1 aut... | Jul 30, 2025 |
| D-0572-2025 | Class II | Xolair (omalizumab injection), 75 mg/0.5 ml, Rx... | Jul 30, 2025 |
| D-0393-2025 | Class II | Wegovy (semaglutide) injection, 2.4 mg/0.75 mL,... | Apr 9, 2025 |
| D-0131-2024 | Class I | LEADER brand Eye Irritation Relief (Polyvinyl a... | Oct 31, 2023 |
Frequently Asked Questions
Stop using the medication immediately and contact your pharmacist. A mislabeling recall can range from a minor technical error (wrong font size) to a serious mix-up where one drug is inside another drug's packaging. If you received a medication that looks or acts differently than expected, or if you experienced unexpected effects, tell your doctor immediately. The pharmacist can verify whether your specific lot is affected and provide a replacement. Report any adverse effects experienced to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.